表紙
市場調查報告書

結合型疫苗的全球市場 - 規模,佔有率,預測,及機會分析

Conjugate Vaccine Market - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026

出版商 Coherent Market Insights 商品編碼 883790
出版日期 內容資訊 英文 186 Pages
商品交期: 2-3個工作天內
價格
Back to Top
結合型疫苗的全球市場 - 規模,佔有率,預測,及機會分析 Conjugate Vaccine Market - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026
出版日期: 2019年06月11日內容資訊: 英文 186 Pages
簡介

這份報告提供全球結合型疫苗市場的相關調查,彙整市場成長及阻礙因素,法規及趨勢,各產品類型·疾病適應症·病原體類型·患者類型·地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 研究的目的及假設

  • 研究目的
  • 假設
  • 簡稱

第2章 市場概要

  • 報告的說明
    • 市場定義和範圍
  • 摘要整理
    • 各產品類型
    • 各疾病適應症
    • 各病原體類型
    • 各患者類型
    • 各地區
  • COM (Coherent Opportunity Map)

第3章 市場動態,法規及趨勢分析

  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 市場趨勢
  • 主要的開發
  • 產品平台分析
  • 投資和政府的配合措施
  • GAVI及PATH計劃詳細內容
  • 合併及收購
  • 法規方案
  • 波特的五力分析
  • PEST分析

第4章 全球結合型疫苗市場:各產品類型

  • 簡介
  • 單價結合型疫苗
  • 多價結合型疫苗

第5章 全球結合型疫苗市場:各疾病適應症

  • 簡介
  • 肺炎球菌
  • 流感
  • 腦膜炎
  • 傷寒症

第6章 全球結合型疫苗市場:各病原體類型

  • 簡介
  • 細菌
  • 病毒

第7章 全球結合型疫苗市場:各患者類型

  • 簡介
  • 小兒科
  • 成人

第8章 全球結合型疫苗市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東
  • 非洲

第9章 競爭情形

  • 熱圖分析
  • 企業簡介
    • Sanofi S.A.
    • Pfizer, Inc.
    • Merck & Co., Inc.
    • GlaxoSmithKline plc.
    • Bharat Biotech
    • Serum institute of India Pvt. Ltd
    • Biological E. Limited.
    • Bio-Med
  • 分析師的意見

第10章 章節

  • 參考文獻
  • 調查方法
  • 本公司與銷售方面

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Conjugate vaccine is a combination of a weak antigen with a strong antigen so to provide active immunization against immune system having a stronger response to the weak antigen. In a conjugate vaccine, the weak antigen is covalently attached to a strong antigen and triggers stronger immunological response to the weak antigen. The weak antigen is a polysaccharide that is attached to strong protein antigen.

Conjugate vaccines target several leading causes of vaccine-preventable deaths. Advantages of conjugate vaccines include their ability to elicit immunological memory and to reduce asymptomatic carriage of the bacteria, resulting in marked herd immunity. These vaccines offer immunization from different bacterial strains. For instance, according to the Centers for Disease Control and Prevention (CDC) April 2019 data, pneumococcal conjugate vaccine (called PCV13) protects against 13 types of pneumococcal bacteria.

Market Dynamics:

Increasing cases of infectious diseases such as typhoid, pneumonia, and others is expected to drive the global conjugate vaccine growth. For instance, according to a study published in Science Direct Journal in 2017, 11.9 - 26.9 million cases of typhoid fever occur each year in low- and middle-income countries (LMICs) Moreover, as per the WHO 2016 data, around one million children globally die from pneumonia every year and there has been an increasing demand for safe and effective vaccines that could prevent these deaths.

Healthcare facilities are looking forward to expand their facilities with advanced technologies to create innovative and cost-effective solutions to address barriers to universal vaccination, which in turn contributing to the growth of the global conjugate vaccine market. For instance, on April 25, 2016, innovative smart phones with an app has been provided to various healthcare facilities of northern Mozambique, Africa for 1 year, through the combined partnership of GSK and Vodafone, with funding from GAVI Global Alliance for Vaccines and Immunisation) and USAID (United States Agency for International Development) under mVacciNation pilot program.

This app enables healthcare facilities to report regularly on vaccine stock levels and refrigerator temperatures, improving critical supply chain and cold chain management. Furthermore, it helps health workers to register patients, view their vaccination histories, and also allows to send reminders to registered patients for their next vaccination.

However, there are some challenges in global implementation of protein conjugate polysaccharide vaccines which may hamper the growth of conjugate vaccine market. For instance, according to the NCBI 2014 article, challenges in implementation of conjugate vaccines includes replacement by nonvaccine serotypes, capsule switching, time duration of the antibody protective effect following vaccination, cost of the vaccines, program costs, lack of knowledge of the disease burden, and targeting population groups for vaccination.

Key features of the study:

  • This report provides in-depth analysis of the global conjugate vaccine market, market size (US$ Mn), and compound annual growth rate (CAGR %) over the forecast period (2018-2026), considering 2017, as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global conjugate vaccine market based on the following parameters - company overview, financial performance, Technology portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Sanofi S.A, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline plc., Bharat Biotech, Serum institute of India Pvt. Ltd., Biological E. Limited, and Bio-Med
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future technology launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global conjugate vaccine market report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers for global conjugate vaccine market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Conjugate vaccine market, By Product Type:
    • Monovalent Conjugate Vaccine
    • Multivalent Conjugate Vaccine
  • Global Conjugate vaccine market, By Disease Indication:
    • Pneumococcal
    • Influenza
    • Meningococcal
    • Typhoid
  • Global Conjugate vaccine market, By Pathogen Type:
    • Bacterial
    • Viral
  • Global Conjugate vaccine market, By Patients Type:
    • Pediatric
    • Adults
  • Global Conjugate vaccine market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Product Type:
    • Monovalent Conjugate Vaccine
    • Multivalent Conjugate Vaccine
      • By Disease Indication:
    • Pneumococcal
    • Influenza
    • Meningococcal
    • Typhoid
      • By Pathogen Type:
    • Bacterial
    • Viral
      • By Patients Type:
    • Pediatric
    • Adults
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Product Type:
    • Monovalent Conjugate Vaccine
    • Multivalent Conjugate Vaccine
      • By Disease Indication:
    • Pneumococcal
    • Influenza
    • Meningococcal
    • Typhoid
      • By Pathogen Type:
    • Bacterial
    • Viral
      • By Patients Type:
    • Pediatric
    • Adults
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Product Type:
    • Monovalent Conjugate Vaccine
    • Multivalent Conjugate Vaccine
      • By Disease Indication:
    • Pneumococcal
    • Influenza
    • Meningococcal
    • Typhoid
      • By Pathogen Type:
    • Bacterial
    • Viral
      • By Patients Type :
    • Pediatric
    • Adults
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Product Type:
    • Monovalent Conjugate Vaccine
    • Multivalent Conjugate Vaccine
      • By Disease Indication:
    • Pneumococcal
    • Influenza
    • Meningococcal
    • Typhoid
      • By Pathogen Type:
    • Bacterial
    • Viral
      • By Patients Type :
    • Pediatric
    • Adults
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Product Type:
    • Monovalent Conjugate Vaccine
    • Multivalent Conjugate Vaccine
      • By Disease Indication:
    • Pneumococcal
    • Influenza
    • Meningococcal
    • Typhoid
      • By Pathogen Type:
    • Bacterial
    • Viral
      • By Patients Type :
    • Pediatric
    • Adults
    • Africa
      • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
      • By Product Type:
    • Monovalent Conjugate Vaccine
    • Multivalent Conjugate Vaccine
      • By Disease Indication:
    • Pneumococcal
    • Influenza
    • Meningococcal
    • Typhoid
      • By Pathogen Type:
    • Bacterial
    • Viral
      • By Patients Type :
    • Pediatric
    • Adults
  • Company Profiles
    • Sanofi S.A *
      • Company Overview
      • Technology Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Pfizer, Inc.
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Bharat Biotech.
    • Serum institute of India Pvt. Ltd.
    • Biological E. Limited
    • Bio-Med

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Product Type
    • Market Snippet, By Disease Indication
    • Market Snippet, By Pathogen Type
    • Market Snippet, By Patient Type
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Product Pipeline Analysis
  • Investments and Government Initiatives
  • GAVI and PATH Program Details
  • Merger and Acquisition
  • Regulatory Scenario
  • PORTER'S Five Forces
  • PEST Analysis

4. Global Conjugate Vaccine Market, By Product Type, 2016 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Monovalent Conjugate Vaccine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Multivalent Conjugate Vaccine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

5. Global Conjugate Vaccine Market, By Disease Indication, 2016 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Pneumococcal
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Influenza
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Meningococcal
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Typhoid
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

6. Global Conjugate Vaccine Market, By Pathogen Type, 2016 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Bacterial
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Viral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

7. Global Conjugate Vaccine Market, By Patient Type, 2016 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Pediatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Adult
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

8. Global Conjugate Vaccine Market, By Regions, 2016 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, By Region, 2016 - 2026
    • Regional Trends
  • North America
    • Market Size and Forecast, By Product Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Pathogen Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Patient Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Product Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Pathogen Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Patient Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Product Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Pathogen Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Patient Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Product Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Pathogen Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Patient Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East
    • Market Size and Forecast, By Product Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Pathogen Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Patient Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Product Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Disease Indication, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Pathogen Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Patient Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country/Region, 2016 - 2026, (US$ Million)
    • Northern Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Sanofi S.A.
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Merck & Co., Inc.
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • GlaxoSmithKline plc.
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Bharat Biotech
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Serum institute of India Pvt. Ltd
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Biological E. Limited.
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Bio-Med
    • Company Overview
    • Technology Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Analyst Views

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact
Back to Top